04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
07:00 , Mar 31, 2016 |  BC Innovations  |  Translation in Brief

Slow and steady

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Bind Therapeutics Inc. (NASDAQ:BIND) have joined forces to stretch the therapeutic index of a kinase inhibitor that had stumbled in the clinic. The partners developed a nanoparticle formulation that slowed...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

AZD2811: Phase I started

AstraZeneca began an open-label, U.S. Phase I trial to evaluate AZD2811 in about 77 patients. A dose-escalation part will determine the dose for the dose-expansion part, which will evaluate AZD2811 alone and with irinotecan. Dosing...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Bind Therapeutics, AstraZeneca preclinical data

In mouse xenograft models of small cell lung cancer (SCLC) and diffuse large B cell lymphoma (DLBCL), AZD2811 inhibited tumor growth and led to tumor regression. Data were presented at the American Association for...